Tarlatamab-DLL3-Null Negative Control Antibody

Tarlatamab-DLL3-Null Negative Control Antibody

SKU: BCBI21m
265.00 USD In stock Buy at Merchant

Tarlatamab is a bispecific monoclonal antibody used to treat extensive-stage small cell lung cancer by engaging T-cells with cancer cells expressing DLL3.

  • The description claims Tarlatamab-DLL3-null negative control antibody retains CD3 binding affinity but abolishes DLL3 binding affinity.
Specifications
Antibody Production Scale
50 ug, 250 ug, 1 mg

AI Readiness

Good foundation, but some important product data is still missing.

74%
3 important fields missing Claim to view full AI report
Data sourced from bicellscientific.com. Last updated: The description was auto-generated by an AI model based on the merchant's description. It may not be accurate or complete.
Claim bicellscientific.com to see AI Product Health

Takes ~2 minutes. No storefront changes.